FFT Enhanced™: Early Multi-Signal Detection Architecture

FFT Enhanced™ is a patent-pending diagnostic platform concept designed to combine multiple biomarker signals into a broader early-detection framework. The goal is to support earlier insight, improve testing pathways, faster accurate diagnostic turnaround, and create a scalable model that can serve rural and underserved communities.

medical laboratory clean

Original FFT Biomarker Foundation

The Original FFT framework is built around four core biomarkers:

• PSA
• CEA
• miR-21
• HE4

FFT Enhanced™ Expanded Biomarker Layer

FFT Enhanced™ builds beyond the original four-marker structure by adding additional biomarker signals intended to strengthen the broader diagnostic framework:

• CA 19-9
• AFP
• MMP-9
• CA-125
• HER4
• Optional sixth enhanced biomarker: PCA3

Designed for Multi-Signal Interpretation

Rather than relying on a single marker, FFT Enhanced™ is designed as a multi-signal platform concept. The goal is to organize biomarker information into a broader architecture that may support earlier insight, signal comparison, faster accurate diagnostic turnaround, and future diagnostic workflow development.

FFT Enhanced™ is in development and is not presented as an FDA-approved diagnostic test unless and until regulatory clearance or approval is obtained.